目的: 梳理日本2022版医保经济性评价指南的相关内容,汲取其中值得我国借鉴的经验,并提出完善建议。方法: 采用比较研究法,对比分析我国现行指南和日本经济性评价指南的差异。结果: 日本医保经济性评价指南（2022版）部分内容值得我国当前医保评价工作参考。结论: 医药经济性评价指南对我国医保事业发展具有重要意义,建议有关部门出台相应指南用于医保评价工作,建立一体化程度更高、协调性更优、专业性更强、更加符合我国国情的中国特色医保评价体系。
Abstract
The paper analyzes the contents of Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council (2022 Edition), draws lessons from it and puts forward proposals. Method: A comparative study was used to analyze the differences between the current guidelines in China and the economic evaluation guidelines in Japan. Result: Some contents of the Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council (2022 Edition) are worth considering during the current medical insurance evaluation in China. Conclusion: Medical economic evaluation guidelines are of great significance to the development of China's medical insurance industry. It is suggested that relevant departments issue guidelines for the evaluation of medical insurance, and establish a Chinese characteristic medical insurance evaluation system with higher integration, better coordination, stronger professionalism, and better meeting the actual conditions of China.
关键词
日本 /
医保 /
经济性评价 /
指南 /
建议
Key words
Japan /
health insurance /
economic evaluation /
guide /
suggestions
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 刘国恩,胡善联,吴久鸿,等.中国药物经济学评价指南[M].中国市场出版社,2020.
[2] SHIROIWA T, FUKUDA T, IKEDA S, et al.Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan[J]. Value in Health the Journal of the International Society for Pharmacoeconomics & Outcomes Research, 2017,20(3):372.
[3] 中央社会保険医療協議会における費用対効果評価の分析ガイドライン第3版[EB/OL]. (2022-02-09)[2023-04-12].https://c2h.niph.go.jp/en/tools/guideline/index.html.
[4] Center for Outcomes Research and Economic Evaluation for Health,C2H[EB/OL].(2022-02-09)[2023-4-12].https://c2h.niph.go.jp/en/results/item.html.
[5] HASEGAWA M, KOMOTO S, SHIROIWA T, et al.Formal Implementation of Cost-Effectiveness Evaluations in Japan: AUnique Health Technology Assessment System[J].Value in Health, 2020,23(1):43-51.
[6] ISPOR. Pharmacoeconomic Guidelines Around the World[EB/OL].[2023-04-12].http://www.ispor.org/PEguidelines/index.asp.
[7] 何旭, 张方.亚洲药物经济学评价指南研究及对中国的启示[J]. 中国新药杂志, 2015,24(19):6.
[8] MHLW. Full Scale Introduction of Cost-Effectiveness Evaluations in Japan[EB/OL].[2023-04-12].https://c2h.niph.go.jp/en/assessment/cost-effectiveness/index.html.
[9] YAMAMOTO M, CURLEY J, HIRATA H.Trends in Open vs. Endoscopic Carpal Tunnel Release: A Comprehensive Survey in Japan[J]. Journal of Clinical Medicine, 2022,11(17):4966.
[10] 周沛宇,席晓宇.生产率损失测量工具的比较研究[J].中国卫生资源, 2022,25(5):7.
[11] STIG, EVENSEN, TORBJøRN, et al. Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers[J]. Schizophrenia Bulletin, 2015.
[12] LUENGO-FERNANDEZ R, LEAL J, GRAY A, et al.Economic burden of cancer across the European Union: a population-based cost analysis.[J].Lancet Oncology, 2013,14(12):1165-1174.
[13] KAMAE I, THWAITES R, HAMADA A, et al.Health technology assessment in Japan: a work in progress[J]. Journal of Medical Economics.
